Page 34 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 34
Chapter 2
Outcome i-PET -/+
3-yr PFS: IF RT: i-t-t: 94.6% 1-yr PFS unfav. IN-RT: 97.3% p-p a: 97.1% vs NFT: 90.8%. 1-yr PFS fav. IN-RT: 100% 3-yr OS: IF RT: 97.1% vs 2-yr PFS: 82%/64% sign NFT: 99.0% NFT 94.9%. NFT 94.7% 2-yr OS: 98%
AVD: 84,5% / i-PET pos:68% 3-yr OS: ABVD:97.0%; AVD: 3-yr PFS: ABVD: 85.5%; 3-yr PFS: 92%/66% sign 97,5% / i-PET pos: 86%
3-yr PFS: 65.2%/52.7% NS 3-yr OS: 68.4%/70.5% NS 3-yr PFS: 81%/57% sign 3-yr OS: 89%/73% NS
2-yr EFS: 82%/50% sign
24.7 mo
4x BEACOPP- esc
2x ABVD
DS 4/5
IHP
3x R-CHOP
R-CHOP14
4x
DLBCL st 80
DLBCL/ gr 71
poor risk 151
II(bulky)/III/
adv st 70
DLBCL
DLBCL
IV
3B FL
2-yr PFS: 76% /42% NS 2-yr PFS: 74% /67% NS 3-yr OS: 93%/69% NS 2-yr OS: 88%/78% NS
Median FUP
i-PET positive therapy
i-PET negative therapy
39.7 mo
42.8 mo
R-BEAM ASCT 1x R-DICEP + BEAM ASCT 2x R-IFE +
60 mo
1x ABVD + RT
IF RT or NFT
DS 3/4/5
IHP
2x ABVD
st I/II supra- 1137 diaphragmatic HL
RCT
Raemaekers/ 2014
EORTC
9
H10
4.6 yr
32 mo
BEACOPP-esc BEACOPP-14 or
1x ABVD+INRT 2xABVD+INRT Unfavorable: 2x ABVD or 4x ABVD or 4x ABVD or Favorable: 4x ABVD 4x AVD
35 mo
4th R-CHOP +4x Z-BEAM ASCT 3x R-ICE + R-ICE
41 mo
1.1 yr
2 yr
2x BEACOPP- esc + IF RT
2x ABVD
DS 4/5
2x ABVD
BEACOPP-esc + Unfavorable: 2x 6x BEACOPP- 2x BEACOPP- Favorable: esc+ INRT esc INRT
Table 1. Studies with I-PET adapted therapy in Hodgkin lymphoma and diffuse large B-cell lymphoma.
2x R-CHOP +2R
R-MegaCHOP
3x
>Liver at
>1 site
IHP
3x R-Mega
R-CHOP21
CHOP
2x
2x R-CHOP
criteria’
‘ECOG
4x R-CHOP
criteria Pos
DS 4/5
2x ABVD
st II-IV HL 1137
phase
RCT
II
12
11
Press/US 2016
Johnson/ 2015
intergroup
S0816
RATHL
i-PET after
Number
Type +stage
Design
Year
3x ABVD
non-bulky HL st IA/IIA 571
RCT
DS 4/5
2x ABVD
st III/IV HL 336
2x ABVD
non-bulky st 164
st IIB/III/IV 50
I/II HL
HL
8
Radford/ 2015 Author/
RAPID
Study
HL
phase
phase
phase
phase
II
II
II
II
2014 phase
II
2014 phase
II
22
21
24
20
Ganesan 2015
Hertzberg 2015
25
Straus/ 2015
Swinnen/ 2015
23
CALGB
Alliance
DLBCL
50604
E3404
Stewart
Pardal
32
